ASCO 2025 Impact Survey: What’s Shaping the Future of Oncology
Discover what 81 oncologists identified as the most influential clinical trial results, emerging therapies and treatment shifts at ASCO 2025 and how they could reshape cancer care in the next three to five years.
Which cancer therapies caught the most attention at ASCO 2025? According to our latest survey, oncologists are prioritizing multi-targeted antibodies, autologous CAR-T and high-impact molecular targets like HER2, BRAF V600E and BCMA. With gastrointestinal and lung cancers topping the list for expected treatment shifts, this report highlights the clinical data most likely to redefine standard of care and which companies are leading the charge.
Fill out the form to download now and explore the oncology innovations driving next-gen cancer treatment strategies.
Related Content
Looking for exclusive insight?
